

## **Iris Grossman, PhD**

**Chief Therapeutics Officer, Eleven Therapeutics**

On the leading edge of Personalized Medicine, Big Data Analytics and BioPharmaceutical R&D for >20 years, Iris is the Chief Therapeutics Officer of Eleven Therapeutics, where she oversees the strategy and development of a pipeline of xRNAs – synthetic, chemically modified extended-release RNA therapeutics discovered by the company's platforms. Eleven uniquely marries combinatorial chemistry, synthetic biology and A.I. to decipher the structure-activity relationship, as well as targeted delivery of xRNAs addressing unmet medical needs in metabolic, hematologic and infectious disease. Prior to joining Eleven, Iris served as Chief Scientific Officer (CAMP4, Amide Technologies (acting)) and consulted for top VCs in the Boston area. Prior to that, Dr. Grossman held leadership positions in, or consulted for Big Pharma (GSK, Eli Lilly, Takeda and Teva – where she rose to the position of VP, Head of Early-Stage Development).

Iris specializes in leveraging multi-dimensional genomic insights and eHealth as engines of therapeutic discovery, development and lifecycle management across a wide range of modalities and therapeutic areas. As such, Dr. Grossman serves as Chairman of the Pharma/Life Sciences SAB at BC Platforms, and as Strategic Founding Advisor at Modulight.bio, and CGRP Diagnostics. She was a pioneering Steering Committee member of Tipa (Maccabi's biobank), is an active member and strategic advisor to the 8400 Healthcare network, and chairs several initiatives as an Executive Women In Bio (eWIB) member.

Iris has championed various multi-year, multi-million dollar partnerships and collaborations, as well as won multiple awards, throughout her career, including the prestigious Top 40 under 40 award (2013) by Globes – Israel's business arena, and various recognition awards for contributions to R&D programs and cutting edge science. Dr. Grossman earned her B.Sc. in medicine at the Technion, and a Ph.D. in medicine, population genomics and pharmacogenetics from the Technion, co-mentored by the Weizmann Institute. Her post-doc fellowship in Personalized Medicine and Population Genomics was conducted at Duke university. She recently completed a Harvard Business School Executive HealthTech program and a Board Room Ready certification course at Georgetown University (via eWIB).